Building on our previous work showing that CCG-203971 inhibits melanoma metastasis [20] and that it can reverse BRAF-inhibitor resistance [35], here, we evaluated the pharmacological potential of CCG-222740, a more potent analog of CCG-203971, in combination with a MEK inhibitor (trametinib) in NRAS-mutant melanoma cells. Here, MAP2K7 is linked to melanoma.